This little announcement should prop up the recent falling SP until we get the half yearly with updated sales figures.
With such widespread use on a range of conditions the completion of the BARDA trial (while important as an evidence base) becomes much less significant. By the time the trial is finished (remembering that the 1st 10 patients is just a feasability trial...then they have a 100-150 patient trial to complete) use of Novosorb will be the norm with multiples of those numbers having already being treated successfully.
Already beginning to feel like we a conquering the US. Must be a fair level of excitement at head office. Can't wait for the fast track to a CE mark and then bring on Europe too.
Ann: First US Surgeon Podium presentations of Novosorb BTM, page-15
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.30 |
Change
0.000(0.00%) |
Mkt cap ! $1.587B | |||
| Open | High | Low | Value | Volume |
| $2.34 | $2.35 | $2.27 | $1.711M | 744.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 14000 | $2.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.30 | 13896 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |